4SCAR-GD2 (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug Name4SCAR-GD2 (Shenzhen Geno-Immune Medical Institute)
Drug Alias Nameanti-GD2 CAR T-cell therapy (neuroblastoma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionDisialoganglioside GD2 modulators
TargetsDisialoganglioside GD2
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesSouthern Medical University Zhujing HospitalShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShenzhen Geno-Immune Medical Institute
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A